FGFR2 and gastric cancer: Indeed, this response in advanced solid malignancy, as well as preclinical data in FGFR2-amplified gastric cancers to dovitinib, sparked the GASDOVI phase II clinical trial investigating dovitinib in FGFR2-amplified gastric cancer; the result of this has yet to be publicly reported.